27446916|t|Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
27446916|a|Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in Western men. Despite its prevalence, PCa has proven very difficult to propagate in vitro. PCa represents a complex organ-like multicellular structure maintained by the dynamic interaction of tumoral cells with parenchymal stroma, endothelial and immune cells, and components of the extracellular matrix (ECM). The lack of PCa models that recapitulate this intricate system has hampered progress toward understanding disease progression and lackluster therapeutic responses. Tissue slices, monolayer cultures and genetically engineered mouse models (GEMM) fail to mimic the complexities of the PCa microenvironment or reproduce the diverse mechanisms of therapy resistance. Moreover, patient derived xenografts (PDXs) are expensive, time consuming, difficult to establish for prostate cancer, lack immune cell-tumor regulation, and often tumors undergo selective engraftments. Here, we describe an interdisciplinary approach using primary PCa and tumor initiating cells (TICs), three-dimensional (3D) tissue engineering, genetic and morphometric profiling, and humanized mice to generate patient - derived organoids for examining personalized therapeutic responses in vitro and in mice co-engrafted with a human immune system (HIS), employing adaptive T-cell- and chimeric antigen receptor- (CAR) immunotherapy. The development of patient specific therapies targeting the vulnerabilities of cancer, when combined with antiproliferative and immunotherapy approaches could help to achieve the full transformative power of cancer precision medicine.
27446916	0	32	Personalized Medicine Approaches	T061	C2718059
27446916	36	51	Prostate Cancer	T191	C0600139
27446916	52	61	Employing	T169	C0457083
27446916	62	69	Patient	T101	C0030705
27446916	70	77	Derived	T080	C1441547
27446916	78	80	3D	T082	C0450363
27446916	81	90	Organoids	T024	C0029250
27446916	95	109	Humanized Mice	T015	C0025929
27446916	110	125	Prostate cancer	T191	C0600139
27446916	127	130	PCa	T191	C0600139
27446916	144	150	common	T081	C0205214
27446916	151	161	malignancy	T191	C4282132
27446916	182	188	common	T081	C0205214
27446916	189	194	cause	T169	C0015127
27446916	198	210	cancer death	T081	C1516192
27446916	214	221	Western	T082	C1705493
27446916	222	225	men	T098	C0025266
27446916	251	254	PCa	T191	C0600139
27446916	271	280	difficult	T080	C0332218
27446916	294	302	in vitro	T080	C1533691
27446916	304	307	PCa	T191	C0600139
27446916	321	328	complex	T080	C0439855
27446916	329	339	organ-like	T023	C0178784
27446916	340	363	multicellular structure	T082	C0678594
27446916	364	374	maintained	T169	C1314677
27446916	382	389	dynamic	T169	C0729333
27446916	390	401	interaction	T169	C1704675
27446916	405	418	tumoral cells	T025	C0597032
27446916	424	442	parenchymal stroma	T025	C0682552
27446916	444	455	endothelial	T025	C0225336
27446916	460	472	immune cells	T025	C0312740
27446916	478	488	components	T026	C0243092
27446916	496	516	extracellular matrix	T024	C0015350
27446916	518	521	ECM	T024	C0015350
27446916	528	532	lack	T080	C0332268
27446916	536	539	PCa	T191	C0600139
27446916	540	546	models	T050	C1516211
27446916	591	599	hampered	T079	C0205421
27446916	600	608	progress	T169	C1280477
27446916	616	629	understanding	T041	C0162340
27446916	630	649	disease progression	T046	C0242656
27446916	654	664	lackluster	T080	C0205222
27446916	665	686	therapeutic responses	T201	C0521982
27446916	688	701	Tissue slices	T062	C1519528
27446916	703	721	monolayer cultures	T059	C1510803
27446916	726	761	genetically engineered mouse models	T050	C1522222
27446916	763	767	GEMM	T050	C1522222
27446916	769	773	fail	T169	C0231175
27446916	787	799	complexities	T169	C0237523
27446916	807	810	PCa	T191	C0600139
27446916	845	852	diverse	T080	C1880371
27446916	853	863	mechanisms	T169	C0441712
27446916	867	874	therapy	T061	C0087111
27446916	875	885	resistance	T169	C4281815
27446916	897	923	patient derived xenografts	T050	C4050317
27446916	925	929	PDXs	T050	C4050317
27446916	946	960	time consuming	T080	C3827829
27446916	962	971	difficult	T080	C0332218
27446916	975	984	establish	T080	C0443211
27446916	989	1004	prostate cancer	T191	C0600139
27446916	1006	1010	lack	T080	C0332268
27446916	1011	1039	immune cell-tumor regulation	T040	C1819849
27446916	1051	1057	tumors	T191	C0027651
27446916	1076	1088	engraftments	T039	C0301944
27446916	1111	1137	interdisciplinary approach	T061	C0870721
27446916	1144	1151	primary	T080	C0205225
27446916	1152	1155	PCa	T191	C0600139
27446916	1160	1182	tumor initiating cells	T025	C1956421
27446916	1184	1188	TICs	T025	C1956421
27446916	1191	1208	three-dimensional	T082	C0450363
27446916	1210	1212	3D	T082	C0450363
27446916	1214	1232	tissue engineering	T061	C0596171
27446916	1234	1241	genetic	T059	C2986505
27446916	1246	1268	morphometric profiling	T059	C0200760
27446916	1274	1288	humanized mice	T015	C0025929
27446916	1301	1308	patient	T101	C0030705
27446916	1311	1318	derived	T080	C1441547
27446916	1319	1328	organoids	T024	C0029250
27446916	1343	1355	personalized	T080	C1709510
27446916	1356	1377	therapeutic responses	T201	C0521982
27446916	1378	1386	in vitro	T080	C1533691
27446916	1394	1398	mice	T015	C0025929
27446916	1399	1411	co-engrafted	T169	C0700106
27446916	1419	1438	human immune system	T022	C0020962
27446916	1440	1443	HIS	T022	C0020962
27446916	1456	1464	adaptive	T169	C0231193
27446916	1465	1472	T-cell-	T025	C0039194
27446916	1477	1503	chimeric antigen receptor-	T116,T129,T192	C4039583
27446916	1505	1508	CAR	T116,T129,T192	C4039583
27446916	1510	1523	immunotherapy	T061	C0021083
27446916	1544	1551	patient	T101	C0030705
27446916	1552	1560	specific	T080	C0205369
27446916	1561	1570	therapies	T061	C0087111
27446916	1571	1580	targeting	T169	C1521840
27446916	1585	1600	vulnerabilities	T033	C1821973
27446916	1604	1610	cancer	T191	C0600139
27446916	1617	1625	combined	T080	C0205195
27446916	1631	1648	antiproliferative	T061	C0087111
27446916	1653	1666	immunotherapy	T061	C0021083
27446916	1667	1677	approaches	T061	C0087111
27446916	1709	1723	transformative	T169	C0205245
27446916	1724	1729	power	T081	C3854080
27446916	1733	1739	cancer	T191	C0600139
27446916	1740	1758	precision medicine	T061	C2718059